Fulcrum Cash and Securities Decrease to $333.3 Million
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 27 2026
0mins
Should l Buy FULC?
As of March 31, cash, cash equivalents, and marketable securities were $333.3M, compared to $352.3M as of December 31, 2025. The decrease of $19M was primarily due to cash used to fund operating activities in 2026. "The strength of the clinical data presented in the first quarter further reinforce our conviction in pociredir's potential to address the underlying biology of sickle cell disease," said Alex Sapir, Fulcrum's president and CEO. "The magnitude of HbF induction and improvements in markers of hemolysis and anemia observed to date support our upcoming discussions with the FDA as we prepare for a potential registration-enabling study in the second half of 2026. With a strong balance sheet extending our cash runway into 2029, we are well positioned to advance pociredir through the next phase of clinical development."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy FULC?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on FULC
Wall Street analysts forecast FULC stock price to rise
11 Analyst Rating
9 Buy
1 Hold
1 Sell
Moderate Buy
Current: 7.000
Low
7.00
Averages
16.80
High
25.00
Current: 7.000
Low
7.00
Averages
16.80
High
25.00
About FULC
Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases in areas of high unmet medical need. The Company's lead clinical program is pociredir, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease (SCD). It uses technology to identify drug targets that can modulate gene expression to treat the known root cause of gene mis-expression. In addition to its product candidates, the Company has developed a discovery approach that it employs to systematically identify and validate cellular drug targets that can potentially modulate gene expression to treat known root causes of genetically defined rare diseases. The Company continues to advance its program for the potential treatment of inherited aplastic anemias, such as Diamond-Blackfan anemia (DBA), Shwachman-Diamond syndrome, and Fanconi anemia.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Fulcrum Therapeutics Grants Stock Options to New Employees
- Stock Option Grant: Fulcrum Therapeutics granted 55,500 stock options to two new employees at an exercise price of $7.02 per share, reflecting the company's commitment to attracting talent to enhance its research and development capabilities.
- Incentive Plan Context: This grant is made under the company's 2022 Inducement Stock Incentive Plan, complying with Nasdaq Listing Rule 5635(c)(4), demonstrating Fulcrum's strategic planning in talent acquisition to boost overall competitiveness.
- Option Structure Design: The options have a ten-year term with a four-year vesting schedule, where 25% vests on the first anniversary and 6.25% vests quarterly thereafter, which not only incentivizes long-term employee retention but also ensures team stability to support ongoing business growth.
- Company Strategic Positioning: Fulcrum focuses on developing small molecules to improve the lives of patients with rare genetic diseases, particularly targeting sickle cell disease, showcasing the company's innovative capabilities and market potential in the biopharmaceutical sector, thereby reinforcing its industry position.
See More
Fulcrum (FULC) Q1 2026 Earnings Transcript
See More
Fulcrum Therapeutics Q1 Earnings Beat Expectations
- Earnings Beat: Fulcrum Therapeutics reported a Q1 GAAP EPS of -$0.25, exceeding expectations by $0.05, indicating some financial resilience despite ongoing losses.
- Strong Cash Position: As of Q1 2026, the company holds $333.3 million in cash, cash equivalents, and marketable securities, providing a cash runway into 2029, which bolsters investor confidence in its future operations.
- Market Outlook: While Fulcrum shows strong HbF signals, its narrow total addressable market (TAM) presents challenges in expanding market share, potentially impacting long-term growth prospects.
- Rating Maintained: Analysts have maintained a 'Hold' rating on Fulcrum Therapeutics, reflecting a cautious outlook on its short-term profitability while indicating the need for investors to monitor its strategic developments moving forward.
See More
Fulcrum Therapeutics Grants Stock Options to New Employee
- Stock Option Grant: Fulcrum Therapeutics granted 34,000 stock options to a new employee at an exercise price of $7.81 per share, reflecting the closing price on March 2, 2026, aimed at attracting talent and strengthening the company's team.
- Incentive Plan Context: This grant is made under Fulcrum's 2022 Inducement Stock Incentive Plan, complying with Nasdaq Listing Rule 5635(c)(4), demonstrating the company's commitment to attracting and retaining key talent.
- Option Structure: The options have a ten-year term and vest over four years, with 25% vesting on the first anniversary and an additional 6.25% vesting quarterly, ensuring continued employee contribution during their tenure with the company.
- Company Mission: Fulcrum focuses on developing small molecules to improve the lives of patients with genetically defined rare diseases, with its lead clinical program pociredir aimed at increasing fetal hemoglobin expression to treat sickle cell disease, highlighting the company's strategic positioning in areas of high unmet medical need.
See More
Significant Milestones in Biotech Sector This Week
- FDA Drug Approvals: Armata Pharmaceuticals' AP-SA02 received FDA's QIDP designation, granting five years of market exclusivity and paving the way for a Phase 3 trial in 2026, which is expected to significantly enhance the company's competitive edge in the antibiotic market.
- Weight Loss Innovation: Allurion Technologies' gastric balloon system gained FDA approval, offering a non-surgical weight loss option for patients with a BMI of 30-40, which is anticipated to expand the company's market share in the obesity sector.
- Acquisition Deal: Gilead Sciences is acquiring Arcellx for $115 per share, totaling $7.8 billion, a move that will strengthen Gilead's position in cell therapy and enhance its collaboration with Kite Pharma.
- Clinical Trial Developments: Novo Nordisk's CagriSema missed key goals in its trial against Zepbound, although it demonstrated a favorable safety profile, which may influence future market strategies.
See More
Fulcrum Therapeutics Reports Phase 1b Trial Results Amid Stock Decline
- Clinical Trial Results: Fulcrum Therapeutics reported that in its Phase 1b trial for pociredir, the 20 mg cohort showed a 12.2% increase in mean absolute fetal hemoglobin (HbF) at 12 weeks, significantly outperforming the 8.6% increase in the 12 mg cohort, indicating the drug's potential in enhancing HbF levels.
- Safety Analysis: The trial reported no serious adverse events, although one patient discontinued due to an unrelated Grade 5 serious adverse event; overall, the strong safety profile could support future registration trials.
- Future Plans: Fulcrum intends to initiate a potential registration-enabling trial in the second half of 2026 and plans to engage with the European Medicines Agency in mid-2026 for feedback on the next trial design, demonstrating a proactive approach to development.
- Financial Position: As of 2025, Fulcrum had $352.3 million in cash and cash equivalents, projected to sustain operations through 2029, despite a 10.01% drop in stock price following the latest announcement, reflecting market caution regarding trial outcomes.
See More
Fulcrum Therapeutics Grants Stock Options to New Employees
- Stock Option Grant: Fulcrum Therapeutics granted 55,500 stock options to two new employees at an exercise price of $7.02 per share, reflecting the company's commitment to attracting talent to enhance its research and development capabilities.
- Incentive Plan Context: This grant is made under the company's 2022 Inducement Stock Incentive Plan, complying with Nasdaq Listing Rule 5635(c)(4), demonstrating Fulcrum's strategic planning in talent acquisition to boost overall competitiveness.
- Option Structure Design: The options have a ten-year term with a four-year vesting schedule, where 25% vests on the first anniversary and 6.25% vests quarterly thereafter, which not only incentivizes long-term employee retention but also ensures team stability to support ongoing business growth.
- Company Strategic Positioning: Fulcrum focuses on developing small molecules to improve the lives of patients with rare genetic diseases, particularly targeting sickle cell disease, showcasing the company's innovative capabilities and market potential in the biopharmaceutical sector, thereby reinforcing its industry position.
See More
Fulcrum (FULC) Q1 2026 Earnings Transcript
See More
Fulcrum Therapeutics Q1 Earnings Beat Expectations
- Earnings Beat: Fulcrum Therapeutics reported a Q1 GAAP EPS of -$0.25, exceeding expectations by $0.05, indicating some financial resilience despite ongoing losses.
- Strong Cash Position: As of Q1 2026, the company holds $333.3 million in cash, cash equivalents, and marketable securities, providing a cash runway into 2029, which bolsters investor confidence in its future operations.
- Market Outlook: While Fulcrum shows strong HbF signals, its narrow total addressable market (TAM) presents challenges in expanding market share, potentially impacting long-term growth prospects.
- Rating Maintained: Analysts have maintained a 'Hold' rating on Fulcrum Therapeutics, reflecting a cautious outlook on its short-term profitability while indicating the need for investors to monitor its strategic developments moving forward.
See More
Fulcrum Therapeutics Grants Stock Options to New Employee
- Stock Option Grant: Fulcrum Therapeutics granted 34,000 stock options to a new employee at an exercise price of $7.81 per share, reflecting the closing price on March 2, 2026, aimed at attracting talent and strengthening the company's team.
- Incentive Plan Context: This grant is made under Fulcrum's 2022 Inducement Stock Incentive Plan, complying with Nasdaq Listing Rule 5635(c)(4), demonstrating the company's commitment to attracting and retaining key talent.
- Option Structure: The options have a ten-year term and vest over four years, with 25% vesting on the first anniversary and an additional 6.25% vesting quarterly, ensuring continued employee contribution during their tenure with the company.
- Company Mission: Fulcrum focuses on developing small molecules to improve the lives of patients with genetically defined rare diseases, with its lead clinical program pociredir aimed at increasing fetal hemoglobin expression to treat sickle cell disease, highlighting the company's strategic positioning in areas of high unmet medical need.
See More
Significant Milestones in Biotech Sector This Week
- FDA Drug Approvals: Armata Pharmaceuticals' AP-SA02 received FDA's QIDP designation, granting five years of market exclusivity and paving the way for a Phase 3 trial in 2026, which is expected to significantly enhance the company's competitive edge in the antibiotic market.
- Weight Loss Innovation: Allurion Technologies' gastric balloon system gained FDA approval, offering a non-surgical weight loss option for patients with a BMI of 30-40, which is anticipated to expand the company's market share in the obesity sector.
- Acquisition Deal: Gilead Sciences is acquiring Arcellx for $115 per share, totaling $7.8 billion, a move that will strengthen Gilead's position in cell therapy and enhance its collaboration with Kite Pharma.
- Clinical Trial Developments: Novo Nordisk's CagriSema missed key goals in its trial against Zepbound, although it demonstrated a favorable safety profile, which may influence future market strategies.
See More
Fulcrum Therapeutics Reports Phase 1b Trial Results Amid Stock Decline
- Clinical Trial Results: Fulcrum Therapeutics reported that in its Phase 1b trial for pociredir, the 20 mg cohort showed a 12.2% increase in mean absolute fetal hemoglobin (HbF) at 12 weeks, significantly outperforming the 8.6% increase in the 12 mg cohort, indicating the drug's potential in enhancing HbF levels.
- Safety Analysis: The trial reported no serious adverse events, although one patient discontinued due to an unrelated Grade 5 serious adverse event; overall, the strong safety profile could support future registration trials.
- Future Plans: Fulcrum intends to initiate a potential registration-enabling trial in the second half of 2026 and plans to engage with the European Medicines Agency in mid-2026 for feedback on the next trial design, demonstrating a proactive approach to development.
- Financial Position: As of 2025, Fulcrum had $352.3 million in cash and cash equivalents, projected to sustain operations through 2029, despite a 10.01% drop in stock price following the latest announcement, reflecting market caution regarding trial outcomes.
See More
